30. Janssen-Heijnen MLG, Smulders S, Lemmens V et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Background: Patients of minority race/ethnicity have lower survival after diagnosis with most types of cancer. Little data are available concerning changes in disparity over time. Here, we examine changes in survival by race/ethnicity of patients with common cancers in two recent time periods.
introduction It has been observed that people of minority race or ethnic background have lower survival after diagnosis with cancer [1, 2] . In the United States, lower survival proportions have been observed for African-Americans (AA) than for non-Hispanic whites (nHw) after diagnosis with breast [2, 3] , colorectal [3] , prostate [3] , lung cancer [1, 3] , and most hematological malignancies including non-Hodgkin's lymphoma (NHL) [4] and acute leukemia (AL) [5] . People of Hispanic ethnic background have been documented to have lower survival for breast [2, 6] , colorectal [2] , prostate [2] , and lung cancer [2] as well as leukemia [7] .
Survival has improved for many cancers over the past 20 years, with major advances in the treatment of a number of cancers, notably breast cancer [8] , myeloma [9] , and NHL [10] . Improvements in screening may have led to earlier detection for some cancers, including colorectal cancer (CRC) [11] , potentially leading to extended survival. Little is known about whether all races and ethnic groups have benefited equally from these advances.
Here, we compare changes in the 5-year survival experience of nHw, AA, and Hispanic patients in the United States in two time periods, 2002-2006 and 1992-1996 . Specific tumor types to be examined are breast, CRC, prostate, lung, and pancreatic cancers, NHL, AL, and multiple myeloma. Breast, CRC, and prostate cancers were selected as examples of cancers for which screening tests and effective therapy for nonmetastatic cancers are available. NHL, AL, and myeloma are examples of cancers for which long-term survival is possible even when the diagnosis is made late in the course of the disease. Lung and pancreatic cancers are cancer types for which no universally accepted screening tests exist and long-term survival is rare, even in apparently early-stage disease.
methods
All data presented in this paper are derived from the 1973-2007 limiteduse database of the Surveillance, Epidemiology, and End Results (SEER) Program [12] . Data included in the SEER 9 database are from populationbased cancer registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound, and San Francisco-Oakland which together cover a population of ∼30 million people.
Five-year survival was evaluated for breast, colorectal, prostate, lung, and pancreatic cancers, NHL, AL, and myeloma. For breast cancer, only cases of female breast cancer were evaluated. The AL was considered as a single group because each individual leukemia type is relatively rare.
Overall and ethnicity-specific 5-year survival were examined for AA, nHw, and Hispanics of any race. Because age is an important factor in survival after a diagnosis of cancer, survival was calculated for two age groups, 15-64 and 65+ years. Cases diagnosed by autopsy or death certificate only were excluded from the analysis.
According to standard practice in population-based cancer survival analysis, relative rather than absolute survival was calculated. Relative survival (RS) reflects survival of cancer patients compared with survival of the general population [13] , calculated as the ratio of absolute survival of cancer patients divided by the expected survival of persons of the corresponding sex, age, and race in the general population. Estimates of expected survival were derived according to the Ederer II method [14] using USA sex-, age-and race-specific life tables published by the Center for Disease Control (CDC) [15] . Because life tables for people of Hispanic ethnicity were not available throughout the period examined, Hispanic patients were categorized by race (AA, white, etc.) rather than ethnic group for calculation of expected survival.
Throughout this paper, period estimates rather than traditional cohortbased estimates of survival are presented. Period analysis provides more up-to-date survival estimates than traditional cohort analysis by exclusively focusing on the survival experience of patients during some recent time period [16] . This is achieved by left truncation of observations at the beginning of that period. It has been shown that period analysis of 5-year RS for a given period of time provides accurate predictions of 5-year RS later observed for cancer patients diagnosed in that period [17] .
A model-based approach was employed to estimate 5-year RS in 1992 5-year RS in -1996 5-year RS in , 1997 5-year RS in -2001 5-year RS in , and 2002 5-year RS in -2006 and to test for trends across those periods. Model-based period analysis has been described in detail elsewhere [18] . Briefly, a Poisson regression model was employed for efficient estimation of survival trends over the three 5-year periods. The number of deaths for each combination of 5-year period and year of follow-up were modeled as a function of 5-year period, which was included as a numerical predictor variable, and year of follow-up, which was included as a categorical variable, using the logarithm of the person-years at risk as All analyses were carried out with the SAS software package using adapted versions of previously described macros for modeled period analysis [18] .
results
Numbers of patients with each cancer type overall and by race or ethnicity are shown in the supplemental Table S1 (available at Annals of Oncology online). All subgroups contained at least 100 individuals with the exception of Hispanics age 65+ with AL. The largest individual group was nHw men with prostate cancer, the smallest group was Hispanics with AL. For each cancer, 7%-11% of patients were either listed as more than one racial/ethnic group, had missing race/ethnicity information, or had a different race or ethnic group listed than any of the above. These patients were not included in the race-specific analysis.
Overall, a statistically significant increase in 5-year RS between 1992-1996 and 2002-2006 was observed for all cancers examined (Table 1 and Table 2 ), although the increase was very small for pancreatic and lung cancers.
Five-year RS increased for patients with breast cancer for all races/ethnic groups and in both older and younger patients, except for Hispanic women 65+. A greater improvement was observed for AA and Hispanic women than for nHw women at +7% points and +7.4% points, respectively, compared with +4.8% points for nHw women. However, both groups still had lower survival than nHw with breast cancer, with 5-year RS at 79.1% for AA, 88.6% for Hispanics, and 92.2% for nHw in 2002-2006. Similarly, 5-year RS among CRC patients increased for all races and ethnic groups, with a greater increase in younger patients. Among older people, the improvement was slightly less for Hispanics than other groups at +3.8% points for nHw, +3% points for AA, and +1% point for Hispanics. Among younger patients, increases in survival were similar among all races and ethnic groups or slightly better for nHw, such that survival continued to be lower in AA (61.5%) and Hispanics (66.2%) than in nHw (71.
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Increased 5-year RS was observed for all races/ethnic groups and both age groups in men with prostate cancer. The increase observed was greatest for AA (+12% points) and marginally higher in Hispanics (+6.1% points) than nHw (+4.8% points) such that survival, which was >8% points lower in AA in 1992-1996, was within 3% points of that of nHw in 2002-2006. It should be noted that in 2002-2006, 5-year RS for prostate cancer approaches 100% for all races, so that further increases may be difficult to detect.
Increases in survival were observed for nHw in pancreatic and lung cancer for both age groups, although the absolute difference was <4% points in all cases. A small increase in survival of 1.7% points was observed for AA aged 15-64 with lung cancer; no increase was observed for either age group for Hispanics. Overall, the prognosis remained very poor for all races/ethnicities and ages, with a small increase in disparity.
Survival improved strongly from 1992-1996 to 2002-2006 for all racial or ethnic groups and each age group for patients with NHL, although the statistical significance was marginal for Hispanics age 65+. When patients aged 15-64 were analyzed, an increase in survival of >20% points was observed for each ethnic group. Overall, 5-year RS was higher for nHw (69.3%) than for AA (61.2%) or Hispanics (65.1%), but the improvement in survival was greater for younger AA (+22.1% points) and Hispanics (+27.1% points) than for nHw (+21.4% points) resulting in a decreased disparity. In contrast, among older patients, the improvement was similar for AA (+11.7% points) and nHw (+11.9% points) but less for Hispanics (+8% points).
For patients with AL, survival increased significantly for nHw in each age group (+10.8 and + 1.5% points, respectively) and for younger Hispanics (+9.3% points) but not for AA or older Hispanics. Thus, the disparity in survival between AA and nHw patients increased between 1992-1996 and 2002-2006. Survival for younger Hispanics was marginally higher than for nHw in 1992-1996 at 29% for Hispanics and 28% for nHw and essentially identical in 2002-2006 at 38.3% and 38.8% , respectively. In 1992-1996, survival was lower for younger AA at 25.8% and there was virtually no change in survival over time. Hence, a large disparity in survival exists in 2002-2006, which was not as evident in 1992-1996.
Five-year RS increased significantly for younger nHw patients with myeloma (+14.9% points) and to a much smaller degree for older nHw patients (+2.2% points). The small increases in survival for AA and older Hispanics and the decrease in survival among younger Hispanic patients were consistent with chance findings. In 1992-1996, 5-year RS was higher for AA (42.7%) and Hispanics (51.6%) than nHw (37.7%) aged 15-64 with myeloma. By 2002-2006, this pattern had reversed, with the highest survival being observed in nHw (52.6%) than AA (44.3%) or Hispanics (46.7%). Interestingly, survival continued to be higher for Hispanics than for nHw among patients aged 65+ at 32.9% and 27.1%, respectively. discussion Five-year cancer survival increased between the 1990s and the early 21st century, even for cancers for which little obvious improvement in treatment has been made. However, we have demonstrated continuing discrepancies in survival, possibly due to inequalities in access to new and high-quality cancer treatments between people of different ethnicities.
The inequality in survival between nHw and people of minority races and ethnicities has decreased for breast and prostate cancer and for NHL, with the clearest examples of catch-up of survival observed for AA with these cancer types. In contrast, little progress has been made in narrowing the disparities in colorectal, lung, and pancreatic cancer and the discrepancy has worsened for AL. Previously, myeloma was one of the few cancers for which survival was greater for AA than for nHw. This pattern was reversed in 2002-2006. Differences in survival in cancer patients of varying racial or ethnic backgrounds may be due to one or more of several factors. First, socioeconomic barriers including prejudice, lack of resources, or lack of medical literacy may prevent patients of minority race or ethnicity from getting appropriate screening for early detection of cancer or from getting timely state-ofthe-art care for a diagnosed malignancy. Second, there may be biological differences between cancers in people of different races or ethnicities. For example, AA women with breast cancer are more likely to have hormone-negative breast cancer, including both 'triple-negative' cancer and possibly HER2 positive cancers [19, 20] . Finally, recent data suggest that AA patients are less likely to be treated at high-volume centers. This may limit these patients' access to state-of-the-art treatment and expert advice, leading to lower survival [21] . This final factor may be of particular importance for the treatment of rare cancers such as AL or cancers for which treatment options are changing rapidly, such as myeloma.
Both breast and prostate cancer are highly treatable and often curable unless metastatic and even in the metastatic setting have non-zero 5-year survival and notable decreases in disparity in survival have occurred in both of these cancers. Reasons for this decrease in discrepancy may include greater use of screening tests and greater access to available treatment modalities. Additionally, some studies have suggested that HER2 positivity in breast cancer may be higher in patients from minority ethnic groups [20] , so that increased use of trastuzumab may be of greater benefit to AA and Hispanic women. Finally, support groups for patients with breast and prostate cancer may aid in ensuring compliance and overcoming socioeconomic inequalities in accessing treatments and navigating the secondary care system, which might original articles Annals of Oncology otherwise compromise care for patients with lower socioeconomic status.
NHL, in contrast to most solid tumors, can be treated at later stages of the disease but lacks an effective screening method. In a previous study of survival in NHL in which survival through 2000-2004 was examined, the improvement in survival was marginally greater for whites than for AA [4] . The current data show the opposite trend, with a greater improvement in survival for Hispanics and AA evident in younger patients. This is consistent with the suggestion that newer more effective treatment protocols are being used more widely and becoming available to more patients, although further empirical work to test this hypothesis is required.
CRC is an exception to the observation that patients from minority ethnic groups have made greater than average increase in survival in cancers for which screening tests are available. There was no overall change in the survival disparity for patients from minority ethnic groups with CRC. This may be due to differences in disease characteristics, i.e. CRC may be more aggressive in AA. However, one publication examining survival in CRC by race in the setting of a Veteran's Affairs hospital found no difference in survival between nHw and AA when access to care was equal [22] . Additionally, AA patients are less likely to receive screening tests for CRC than nHw [23] . This strongly suggests that access to care, whether at the diagnostic or the therapeutic level, is a major contributor to the observed inequalities.
In contrast, little change in 5-year survival was observed for cancers for which few effective treatments exist. Overall survival increased slightly for nHw patients with lung or pancreatic cancer but not for Hispanics or AA with the same cancer types. A smaller proportion of patients from minority ethnic groups have health insurance [24] . This may lead to lower access to specialist centers providing state-of-the-art treatment modalities.
Overall survival has improved for patients with myeloma, with dramatic improvement being observed for younger patients in recent years [25] . This improvement did not extend to patients from minority ethnic groups. These patients are more likely to be uninsured, limiting their access to newer therapeutic options. Similar problems may explain the lack of improvement in survival among minority patients with AL. It is worth noting that minority patients are less likely to receive hematopoietic stem cell transplant, a mainstay of treatment in myeloma and many AL [26] . It is unlikely that the biology of these diseases changed significantly between the two periods. Thus, it is highly likely that unequal access to care is a major factor in the relative lack of progress observed for minority patients with myeloma and AL.
Complete examination of survival by stage is beyond the scope of this study. However, preliminary analysis of stage at presentation for breast cancer and CRC suggest that differential change in stage at presentation may play a role in some of the changes observed. For example, in CRC, for nHw patients, the percentage of patients presenting in stage I increased by ∼4% points (from 23% to 27%) between 1992-1996 and 2002-2006. A smaller increase of 2% points was seen for AA (from 21% to 23%) and no increase was observed for Hispanics. Similarly, a decrease in the proportion of stage IV disease of ∼4.5% points was observed for nHw versus decreases of ∼3% points for AA and Hispanics during the same time period. These differential developments may reflect differences in screening rates. For breast cancer, the proportion of women presenting at stage IV was higher for patients of minority ethnic or racial background, but this disparity tended to decrease over time. The proportion of patients presenting at stage IV decreased for nHw by <1% point between 1992-1996 and 2002-2006, whereas it decreased by >1.5% points for Hispanic and AA patients. Future in-depth examination of survival in breast cancer by race may help clarify to what extent each of the above (i.e. earlier diagnosis due to better screening, better targeted treatments, and better access to care) have contributed to the changes observed and where further work is needed to maximize survival for patients of all racial and ethnic backgrounds.
In considering our results, several limitations should be noted. The SEER database does not contain information regarding chemotherapy and therefore, we cannot definitively state that differences in chemotherapy account for observed differences. Additionally, cancers for which population-based screening tests are available may show increased 5-year survival partially because of early detection, resulting in a longer 'patient career' rather than true changes in the course of the disease. Thus, increases in 5-year survival should be interpreted with some caution, particularly for prostate cancer, for which screening may result in the detection of clinically insignificant cancers.
The reporting of race and ethnicity in SEER has been verified as highly reliable with respect to race and moderately to highly reliable with respect to ethnicity [27] . Hispanic patients are more likely to be misclassified as non-Hispanic than vice versa so that the total numbers of patients classified as Hispanic may be lower than the true value, resulting in larger standard errors for this patient group. However, there is no evidence that the patients so misclassified are of a specific subpopulation with different survival than the rest. Thus, it could have diluted the observed differences between ethnic groups but is very unlikely to have caused spurious findings.
Finally, the lack of availability of life tables for people of Hispanic ethnic origin limits our ability to determine true RS for this group. People of Hispanic origin are estimated to have survival equal to or higher than people of non-Hispanic origin by some authors [28] . The CDC began publishing life tables for people of Hispanic origin starting in 2006 [29] . These tables tend to confirm the 'Hispanic paradox', i.e. that Hispanic people live longer than non-Hispanics despite lower socioeconomic status and lower access to health care. An additional potential confounder is difficulty with data linkage. A recent study demonstrated that cancer survival estimates for Hispanics, particularly foreign-born Hispanics, may be unrealistically high due to failure of linkage of death records to the SEER database [30] . Thus, survival may be overestimated for Hispanics, especially for highly fatal cancers.
In conclusion, increased survival was observed for all cancer types examined, with wide variation in the extent to which the increase extended to people of minority ethnic background. Decreased disparity was observed for patients with some common highly treatable tumors. In contrast, survival Annals of Oncology original articles
